|Bid||43.21 x 4000|
|Ask||43.21 x 2200|
|Day's Range||43.03 - 43.69|
|52 Week Range||34.35 - 46.62|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||56.12|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Boston Scientific preliminarily announced disappointing fourth-quarter sales on Tuesday, sending BSX stock into a tailspin. The biggest shortfall came from cardiac rhythm management.
Shares of Boston Scientific Corp. dropped 6.3% in premarket trading Tuesday, after the medical technology company provided a fourth-quarter sales outlook that was below expectations. On a preliminary basis, sales rose 13.4% to $2.90 billion, below the FactSet consensus of $2.93 billion, as MedSurg revenue rose 9.8%, Rhythm and Neuro grew 3.5%, Cardiovascular increased 18.7% and medical devices rose 11.2%. The company said it is still closing its books for the quarter, but estimates it will report adjusted earnings per share within its previously issued guidance range of 42 cents to 45 cents; the FactSet consensus was 44 cents. The stock has run up 19.8% over the past three months through Monday, while the SPDR Health Care Select Sector ETF has rallied 14.0% and the S&P 500 has gained 10.9%.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Boston Scientific Corp. could be forced to go through with a $275 million acquisition that the Marlborough-based medical device giant had abandoned following a fraud investigation.
We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 44.6% this year and beat the S&P 500 ETFs by […]
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...
One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
This week's military contracting roundup features three contract notices for food distribution, staffing of certified registered nurse anesthetists and neurostimulator implantable devices, as well as solicitations for four contracts at Joint Base San Antonio.
Does the December share price for Boston Scientific Corporation (NYSE:BSX) reflect what it's really worth? Today, we...
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.